Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 89 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $76,128 | -100.0% | 15,600 | 0.0% | 0.00% | – |
| Q3 2022 | $224,952,000 | -4.7% | 15,600 | 0.0% | 0.00% | – |
| Q2 2022 | $236,028,000 | +27.4% | 15,600 | 0.0% | 0.00% | – |
| Q1 2022 | $185,328,000 | -26.7% | 15,600 | 0.0% | 0.00% | – |
| Q4 2021 | $252,876,000 | -62.2% | 15,600 | -33.4% | 0.00% | – |
| Q3 2021 | $668,378,000 | -15.6% | 23,419 | 0.0% | 0.00% | – |
| Q2 2021 | $791,562,000 | +102.9% | 23,419 | +81.5% | 0.00% | – |
| Q1 2021 | $390,096,000 | -53.0% | 12,900 | -23.0% | 0.00% | – |
| Q4 2020 | $829,243,000 | +29.0% | 16,749 | 0.0% | 0.00% | – |
| Q3 2020 | $642,994,000 | -5.5% | 16,749 | +6.3% | 0.00% | – |
| Q2 2020 | $680,357,000 | +225.8% | 15,749 | +96.9% | 0.00% | – |
| Q1 2020 | $208,800,000 | -16.5% | 8,000 | 0.0% | 0.00% | – |
| Q4 2019 | $250,000,000 | – | 8,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |